GSK (GSK) M&A announcement summary

Deal rationale and strategic fit

• Acquisition targets a significant unmet need in food allergy, with over 1.3 million people in the US affected by severe reactions and more than 17 million diagnosed overall.

• Lead asset ozureprubart is a potential best-in-class, long-acting anti-IgE monoclonal antibody, offering less frequent dosing (every 12 weeks) and improved compliance, especially for children.

• Ozureprubart's differentiated, simplified dosing regimen may broaden the eligible patient population, including those currently ineligible for existing anti-IgE therapies.

• The acquisition expands the immunology and inflammation pipeline and leverages an established commercial allergy footprint.

• Provides access to global development and commercialization capabilities, excluding mainland China, Macau, Taiwan, and Hong Kong.

Financial terms and conditions

• Total deal consideration is $2.2 billion, with shareholders receiving $58.00 per share in cash; net upfront investment is $1.9 billion after cash acquired.

• Acquisition grants global rights to ozureprubart, excluding certain Asian markets.

• Success-based milestone and royalty payments will be made to Shanghai Jeyou Pharmaceutical.

• Transaction expected to close in Q1 2026.

Synergies and expected cost savings

• Acquisition leverages an extensive commercial and prescriber base in allergy, supporting rapid uptake and market penetration.